HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis - Takeaways - MDSpire

HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis

  • By

  • Joseph Fokam

  • Aude Christelle Ka’e

  • Bouba Yagai

  • Maria Mercedes Santoro

  • Judith Kose Otieno

  • Natella Rakhmanina

  • Collins Ambe Chenwi

  • Alex Durand Nka

  • Ezechiel Ngoufack Jagni Semengue

  • Davy-Hyacinthe Gouissi

  • Willy Leroi Pabo Togna

  • Nelly Kamgaing

  • Tetang Suzie

  • Desire Takou

  • Georges Teto

  • Tatiana Tekoh

  • Jeremiah Efakika Gabisa

  • Audrey Nayang Mundo

  • Lum Forgwei

  • Naomi-Karell Etame

  • Aurelie Minelle Kengni Ngueko

  • Michel Carlos Tommo Tchouaket

  • Boris Tchounga

  • Patrice Tchendjou

  • Joelle Nounouce Bouba Pamen

  • Rogers Ajeh Awoh

  • Gregory-Edie Halle-Ekane

  • Giulia Cappelli

  • Alexis Ndjolo

  • Francesca Ceccherini-Silberstein

  • Vittorio Colizzi

  • Jean Kaseya

  • Nicaise Ndembi

  • Carlo Federico Perno

  • June 26, 2025

  • 0 min

Share

  • 1

    The prevalence of pretreatment drug resistance (PDR) in children with HIV is 32.48%, significantly higher among those who failed PMTCT interventions.

  • 2

    Acquired drug resistance (ADR) prevalence in pediatric HIV populations is 61.43%, primarily driven by mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs).

  • 3

    Emerging resistance to integrase strand transfer inhibitors (INSTIs) is low at 5.53%, indicating a need for ongoing drug-resistance surveillance in children.

  • 4

    Despite improvements in PMTCT, pediatric HIV infection remains a concern, with only 57% of children aged 0-14 receiving antiretroviral therapy in 2022.

  • 5

    The study highlights the urgent need to phase out pediatric NNRTIs and improve access to effective antiretrovirals to combat drug resistance in children.

Original Source(s)

HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis

  • by Joseph Fokam, Aude Christelle Ka’e, Bouba Yagai, Maria Mercedes Santoro, Judith Kose Otieno, Natella Rakhmanina, Collins Ambe Chenwi, Alex Durand Nka, Ezechiel Ngoufack Jagni Semengue, Davy-Hyacinthe Gouissi, Willy Leroi Pabo Togna, Nelly Kamgaing, Tetang Suzie, Desire Takou, Georges Teto, Tatiana Tekoh, Jeremiah Efakika Gabisa, Audrey Nayang Mundo, Lum Forgwei, Naomi-Karell Etame, Aurelie Minelle Kengni Ngueko, Michel Carlos Tommo Tchouaket, Boris Tchounga, Patrice Tchendjou, Joelle Nounouce Bouba Pamen, Rogers Ajeh Awoh, Gregory-Edie Halle-Ekane, Giulia Cappelli, Alexis Ndjolo, Francesca Ceccherini-Silberstein, Vittorio Colizzi, Jean Kaseya, Nicaise Ndembi, Carlo Federico Perno

  • June 26, 2025

Related Content

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Cladribine treatment in pediatric-onset multiple sclerosis: real-world clinical outcomes and safety insights

FURL vs Mini-PCNL in 2 to 3 cm Stones

Review reports comparable stone-free rates with suction-assisted ureteroscopy